nVerses Capital’s TG Therapeutics TGTX Stock Holding History

nVerses Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,392	Closed	-$250K	–	473
2025 Q4	$250K	Buy	+8,392	New	+$274K	0.56%	84
2024 Q3	–	Sell	-5,800	Closed	-$103K	–	1382
2024 Q2	$103K	Buy	5,800 +1,500	+35%	+$23.9K	0.06%	437
2024 Q1	$65.4K	Buy	+4,300	New	+$68.5K	0.16%	232

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

nVerses Capital's TGTX Position: Q1 2026 in Review

nVerses Capital sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 8,392 shares — an estimated $250K sold.

nVerses Capital first reported a position in TGTX in Q1 2024 and held it in 3 quarters. The position peaked at $250K in Q4 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

nVerses Capital reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
nVerses Capital sold 8,392 TG Therapeutics shares in Q1 2026, an estimated $250K.
nVerses Capital first reported a position in TG Therapeutics in Q1 2024 and held it in 3 quarters.
nVerses Capital's TG Therapeutics position peaked at $250K in Q4 2025.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on nVerses Capital's 13F filing for Q1 2026, filed 13 May 2026.